Post on 17-Dec-2015
American Conference on Pharmacometics American Conference on Pharmacometics –San Diego, CA; April 3-6 2011–San Diego, CA; April 3-6 2011
Population PK modeling incorporating enzyme induction mechanism to Population PK modeling incorporating enzyme induction mechanism to guide the design of optimal dose regimen for an antiviral drugguide the design of optimal dose regimen for an antiviral drug
Jing YuJing Yu1, June Ke, June Ke2, Leo Kawai, Leo Kawai1 1M&S - Novartis Pharma, Cambridge, MA; M&S - Novartis Pharma, Cambridge, MA; 2DMPK – Novartis Pharma, East Hanover, NJDMPK – Novartis Pharma, East Hanover, NJ
Objectives: Respiratory Syncytial Virus (RSV) infection is the leading cause of serious respiratory tract infections in infants, young children, elderly, and immuno-compromised patients throughout the world. RSV604 is a benzodiazepine analog that inhibits RSV replication in vitro. In vitro and clinical studies indicate that RSV604 systemic exposure had potential for a narrow therapeutic concentration range. Therefore, selection of optimal dose regimen required a model which precisely profiles individual PK in the therapeutic range.
Methods: A linear three-compartment PK model with first-order absorption was built with Phase 1 study data including intravenous (IV; 10-200 mg) and oral (PO; 25-150 mg) doses, as population PK model with NONMEM. The linear model suggested a 450 mg loading dose followed by 150 mg BID to satisfy the therapeutic concentration range requirement. However, the highest dose group (200 mg) in the IV Phase 1 study and the 150 and 300 mg dose groups in a later conducted oral Phase 1 study showed the compound didn't accumulate after 5 days of dosing as projected from single dose data. As RSV604 was shown to moderately induce CYP3A4 by in vitro reporter gene assay, a clearance induction model, considering enzyme turn-over, was then examined, using in vitro enzyme induction parameters as initial estimations of in vivo model.
Results: The enzyme induction model fitted all the data from Phase 1 studies well and eliminated the gaps observed in the initial linear model. This model predicted a 600 mg loading dose followed by 300 mg BID would rapidly reach the desired Cmin of 2000 ng/mL but decrease the potential safety risk. The prediction of this enzyme induction model was further validated by the PK data from subsequent clinical studies.
Conclusions: Incorporation of an induction effect in the population PK model increased the accuracy in describing PK data from all Phase 1 studies and predicted an optimal dose regimen to be used in the next stage of drug development.
AbstractAbstract
IntroductionIntroduction
Evidence of enzyme inductionEvidence of enzyme induction
2101 study: exposure at MD (AUCss) vs. SD (AUCinf) tends to be low in high iv dose (200 mg); attenuated accumulation in higher dose
in vitro and animal data suggest CYP3A4 induction: in vitro EC50 =~2750ng/mL
Linear model over-predicts data from the oral Phase 1 study (2103) cohorts 1 & 2
Simulations (linear) vs. 2103 data
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0 50 100 150 200 250 300 350
Time (hr)
Co
nc
(ng
/mL
)
150 mg Sim
300 mg Sim
150 mg Data
300 mg Data
2101: AUCss (MD) /AUC0-inf (SD) vs. Dose
0
1
2
0 50 100 150 200
Dose
AU
Css
/AU
C0-
inf
Enzyme auto-induction modelEnzyme auto-induction model
Dosing
Time (hr)
CL
(L/h
r)
0 50 100 150 200 250 300
24
68
Model prediction for CL (iv)
10 mg25 mg75 mg200 mg
Dosing
Time (hr)
CL
(L/h
r)
0 50 100 150 200 250 300
24
68
Model prediction for CL (iv)
10 mg25 mg75 mg200 mg
Time (hr)
CL
(L/h
r)
0 50 100 150 200 250 300
24
68
Model prediction for CL (iv)
10 mg25 mg75 mg200 mg
Concentration-dependent clearance:
dCLint /dt = Kreg *[1+ Emax *C/(EC50 +C) – CLint/ Clint,0], where C is concentration
When C<< EC50, it can be simplified to
dCLint /dt = Kreg *[1+ Ke *C – CLint/ Clint,0], where Ke = Emax / EC50
Estimated parameters
Kreg = 4.62 L/hr/hr;
Ke = 0.000427 /(ng/mL)Model building and validationModel building and validation
Simulations vs. Data
-500
0
500
1000
1500
2000
2500
3000
3500
4000
0 50 100 150 200 250 300 350
Time (hr)
Co
nc
(n
g/m
L)
150 mg Sim
300 mg Sim
150 mg Data
300 mg Data
2103 study cohorts 1 & 2 data for model fitting (left) and cohort 3 data for model validation (right) Estimated parameters
Clint,0 = 3.21 L/hr
Kreg = 4.62 L/hr/hr
Ke = 0.000427 /(ng/mL)Simulation (induction started from beginning) vs. Data
0
500
1000
1500
2000
2500
3000
3500
4000
4500
0 50 100 150 200 250 300 350
Time (hr)
Co
nc
(n
g/m
L)
450+150 mg Sim
450+150mg Data
New dose regimen for efficacy study New dose regimen for efficacy study
4.543.532.521.510.50
6000
5000
4000
3000
2000
1000
0
TIME (Days)
Co
nc
(ng
/mL
)
Potentially efficacious dose regimen suggested by induction model: 600 mg loading dose followed by 300 mg bid
ConclusionConclusion
The enzyme induction model represents the available clinical data well, although the real mechanism of the nonlinear PK profile needs to be further evaluated. With this model, we have reached a higher level of confidence in designing an optimal dose regimen, 600 mg loading dose followed by 300 mg bid, for the efficacy study in the next stage of drug development.
AcknowledgementsAcknowledgements
The whole RSV604 Team, especially Kathryn Bracken (PJM), Jens Praestgaard (CIS), Russ Wada (M&S), Daniel Stein and Tom Evans (TME).
mRNAfor CYP
CYPEnzyme
CompoundConcentration
Clearance
SynthesisStimulate clearance pathway
Degradation Degradation
TranscriptionAuto-
inductionmRNA
for CYP
CYPEnzyme
CompoundConcentration
Clearance
SynthesisStimulate clearance pathway
Degradation Degradation
TranscriptionAuto-
induction